Medindia LOGIN REGISTER
Medindia

Brodalumab - Indications, Dosage, Side Effects and Precautions

Advertisement

Information about Brodalumab

Generic Name : Brodalumab
Up-to-date prescription details regarding Brodalumab are provided here.

Pronunciation : broe-DAL-ue-mab

Learn the correct pronunciation of the Brodalumab, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.
You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.


Therapeutic Classification : Monoclonal antibodies

Trade Names/Brand Names of Brodalumab

India :


Siliq

Overview of Brodalumab

• Brodalumab is an interleukin -17 receptor A antagonist which was approved by the US FDA on February 2017 for the treatment of moderate-to-severe plaque psoriasis.

Why is Brodalumab Prescribed? (Indications)

Brodalumab is a human monoclonal antibody prescribed to treat moderate-or -severe plaque psoriasis in patients who do not respond to other systemic treatments.
Plaque psoriasis is a skin disease in which the skin has red or scaly patches covered with a silver-white build up of dead skin cells. The lesions usually appears on the knee, elbow, scalp or lower back.
Brodalumab works by blocking inflammation by targeting the interleukin (IL)-17 receptor.

When should Brodalumab not be taken? (Contraindications)

Brodalumab is not recommended in patients with:

• Allergy to the drug
Crohn's disease (Brodalumab worsens the disease)
• Chronic or recurrent infections
• Active tuberculosis
• History of mental illness (anxiety or depression) or a mood disorder
• Age less than 18 years old

What is the dosage of Brodalumab?

• The recommended adult dose is 210 mg injected subcutaneously once a week for 3 consecutive weeks.
• This is followed by injections of 210 mg once for every 2 weeks for a maximum of 16 weeks.

How should Brodalumab be taken?

• Brodalumab comes as a solution or a liquid in a prefilled syringe which has to be injected as a subcutaneous injection (under the skin).
• The prefilled syringe should be used only once by injecting all the solution in the syringe. It should be disposed safely in a puncture-resistant container after use.
• Brodalumab can be injected into the thighs, upper arms or stomach except the navel and the area 2 inches around the navel.
• The syringe should not be shaken and care should be taken not to administer it on a psoriatic patch.

What are the warnings and precautions for Brodalumab?

• Patients and caregivers should be advised about the suicidal ideation and behavior which is associated with brodalumab therapy.

• Anti-tubercular therapy should be initiated prior to brodalumab treatment in patients with latent or active tuberculosis.

• Continuous and close monitoring of patients should be carried out in both during and after brodalumab treatment.

• Monitoring of complete blood cell count during brodalumab therapy is needed as brodalumab reduces the number of white blood cells which leads to infection.

• Patient wallet cards that describe serious adverse effects must be carried by the patient at all times.

• Brodalumab should be avoided in pregnancy and breastfeeding women as there are no adequate data available regarding the safety and efficacy of the drug in these populations.

What are the side effects of Brodalumab?

Common: Influenza, tinea infections, headache, neutropenia, muscle pain.
Gastrointestinal: Nausea, stomach cramps, diarrhea or constipation, loss of appetite, bloody or watery stools.
Central nervous system: New or worsening anxiety or depression, unusual changes in mood or behavior, suicidal ideation
ENT: Pain in the ear, ear drainage, trouble in hearing and breathing, cough, sore throat, symptoms of cold and flu
Skin: Injection site reactions such as redness, pain, itching, bruising or bleeding
Others: Conjunctivitis, candida infections, fatigue, joint pain, urinary tract infections

What are the other precautions for Brodalumab?

• The prefilled syringe, after removing from cold storage, should be allowed to come to a room temperature by keeping it out for at least 30 minutes. They should, however, not be refrigerated again.
• Do not use any other techniques to warm the prefilled syringe such as dropping in hot water or heating in a microwave oven.
• The injection should be inspected for any visible particles prior to administration and should be discarded if it is cloudy.
• Patients should be advised to read the FDA approved labeling which includes the medication guide and the instructions for use before using brodalumab.

What are the Drug Interactions of Brodalumab?

• The use of live vaccines in patients taking brodalumab should be avoided.
• Since the effect of drugs metabolized by the enzyme CYP450 like warfarin and cyclosporine may be altered by brodalumab, monitoring of the treatment may be required.

What are the storage conditions for Brodalumab?

• Brodalumab injection should be stored at a temperature of 2°C to 8°C in its original carton but should not be frozen.
• Prefilled syringes can be stored at a room temperature of up to 25°C in the original carton for a maximum period of 2 weeks and should be discarded if not used after this time limit.
• They should be protected from light and physical damage.
Advertisement
Recommended Reading